Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

SPLICE-BETA RNA splicing therapeutics for beta cell dysfunction and diabetes

Coordinator
Universidad Pompeu Fabra, Spain
Runs
1 September 2026 to 29 February 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101292605

What the project is doing

In the project's own words, from its summary on CORDIS.

Diabetes is a progressive metabolic disorder driven by beta cell dysfunction and failure, ultimately leading to chronic hyperglycemia and severe clinical complications. Current anti-diabetic treatments, including insulin secretagogues and incretin mimetics, primarily aim to control blood glucose levels without addressing the underlying molecular defects that drive beta cell decline, which in some cases even accelerate their exhaustion.

Alternative splicing has recently emerged as a fundamental regulator of beta cell identity, glucose sensing, and insulin secretion, offering a novel therapeutic entry point. Our ERC-funded research uncovered a conserved program of islet-enriched microexons (IsletMICs), 3-51 nt exons controlling key genes in stimulus-secretion coupling. We have shown that splice-switching antisense oligonucleotides (SSOs) targeting specific IsletMICs can potentiate glucose-stimulated insulin secretion in human beta cells.

This ERC PoC will advance a first-in-class RNA therapeutic for diabetes and other beta-cell related diseases through three integrated work packages: (1) develop a high-throughput screening pipeline to systematically test the effects of hundreds of SSOs on beta cell function; (2) targeted delivery using SSO-peptide conjugation and validation in primary human islets and hepatocytes for efficacy and toxicity in vitro studies; and (3) preclinical testing in a diabetic mouse model for biodistribution, safety, and glycemic control under a clinically relevant setting of beta cell dysfunction.

By project completion, we will deliver a high-throughput platform for target discovery with subsequent decisive preclinical evidence, an optimised lead for selective beta cell delivery, and a roadmap for advancing into regulatory studies and engagement with pharmaceutical partners.

Topics

Who is involved

OrganisationCityCountryRole
Universidad Pompeu FabraBarcelonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI